“If you don’t know where you’re going, any road will take you there.”—Oft-cited paraphrase of exchange between the Cheshire Cat and Alice in Lewis Carroll’s classic children’s tale, Alice’s Adventures in Wonderland

Given the overarching role of the U.S. in the world economy, it is no surprise that when the Fed sneezes, central banks around the world catch a cold. During the so-called taper tantrum of 2013, the Fed’s unexpected talk of plans to slow down its bond purchase program resulted in higher interest rates and a stronger dollar, which caused the capital pipelines of emerging markets to freeze. Today, with a tenuous global recovery underway and the threat of the pandemic hanging on, central banks around the world are watching the actions of an increasingly hawkish Fed with hawk eyes (no pun intended). At the same time, we’re seeing global policy divergences as economies emerge from the pandemic environment at different speeds and face different challenges. For investors, this environment could present country-specific opportunities in fixed income, equities, and currencies.

“There is an art to science, and a science in art; the two are not enemies, but different aspects of the whole.” — Isaac Asimov

China’s recent regulatory crackdown and the consequent impact on its financial markets have caught the attention of worldwide media and investors. (A recent post by my colleague Peter Roberto explores the regulatory backdrop.) Given the current environment, I’ve been receiving numerous questions asking if now is the time to double down on Chinese equities. Potential investors are wondering if the recent bounce in some of the hardest-hit stocks could be a sustained run. My belief is that, over the shorter term, headline risks remain elevated for Chinese equities. In the long term, continued economic growth in China may present attractive opportunities for value creation. To avoid potential landmines, however, active management is critical.

Last week, I happily returned to yet another tradition that was disrupted by COVID-19: back-to-school shopping. Although I did not miss paying for the rapidly changing school wardrobes of two teenage girls last year, I welcomed the feeling of normalcy the shopping routine brought to my family. COVID-19 and its associated restrictions have had a huge impact on children—educationally, socially, emotionally, and physically. We’ve all seen this. But did you know that, because of the pandemic, children may grow up to be worse off financially than their parents?

In 2020, the U.S. GDP declined 3.4 percent, yet the S&P 500 was up 18.4 percent. In the first half of 2021, the U.S. GDP grew by 6.4 percent, and the S&P 500 was up by 15.25 percent.

The celebrated “rainbow nation” of South Africa was recently rocked by the worst violence since the nation achieved democracy and ended apartheid in 1994. Many lost their lives, the economy was hit at a time when it was already reeling under the effects of the pandemic, and its capital markets grew nervous.

Australia has been one of the biggest beneficiaries of China’s growth in the past several decades. China’s infrastructure spending after the last two crises—the great financial crisis and the more recent COVID-19 pandemic—created a demand for resources that was largely fulfilled by Australia. Indeed, this demand helped alleviate some of the pain for the Australian economy.

As with the rest of the world, the COVID-19 pandemic had a devastating effect on the European economy, not to mention the continued uncertainty regarding Brexit. The U.S. and China were among the first countries on the path to economic recovery, while Europe struggled to emerge from the lockdowns and had a rough start to its vaccination program.

Last week, the FDA approved Biogen’s Alzheimer’s drug candidate, aducanumab (marketed as Aduhelm). This approval looks likely to be a watershed moment for the biotech industry. The shares of Biogen were halted for the announcement. And as anticipated, they popped once trading resumed.